Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ultan McDermott

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Current Opinion in Genetics & Development|March 11, 2019
Large-scale compound screens and pharmacogenomic interactions in cancerUltan McDermott
Drug Discovery Today|October 24, 2015
Next-generation sequencing and empowering personalised cancer medicineUltan McDermott
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncologyUltan McDermott, Jeff Settleman
Drug Discovery Today|February 21, 2012
Exploiting genetic complexity in cancer to improve therapeutic strategiesMathew J Garnett, Ultan McDermott
Current Opinion in Genetics & Development|March 11, 2014
The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug responseMathew J Garnett, Ultan McDermott
Cell Chemical Biology|July 25, 2017
The Pursuit of Therapeutic Biomarkers with High-Throughput Cancer Cell Drug ScreensSteven P Williams, Ultan McDermott
Molecular Oncology|June 25, 2014
Reading between the lines; understanding drug response in the post genomic eraConstantine C Alifrangis, Ultan McDermott
Methods in Enzymology|April 17, 2008
High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitorUltan McDermott, Sreenath V Sharma, Jeffrey Settleman
Clinical Colorectal Cancer|March 7, 2003
Predictive markers for colorectal cancer: current status and future prospectsDaniel B Longley, Ultan McDermott, Patrick G Johnston
Nature Cancer|February 5, 2022
Genomics-guided pre-clinical development of cancer therapiesHayley E Francies, Ultan McDermott, Mathew J Garnett
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Current Opinion in Genetics & Development|March 11, 2019
Large-scale compound screens and pharmacogenomic interactions in cancerUltan McDermott
Drug Discovery Today|October 24, 2015
Next-generation sequencing and empowering personalised cancer medicineUltan McDermott
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncologyUltan McDermott, Jeff Settleman
Drug Discovery Today|February 21, 2012
Exploiting genetic complexity in cancer to improve therapeutic strategiesMathew J Garnett, Ultan McDermott
Current Opinion in Genetics & Development|March 11, 2014
The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug responseMathew J Garnett, Ultan McDermott
Cell Chemical Biology|July 25, 2017
The Pursuit of Therapeutic Biomarkers with High-Throughput Cancer Cell Drug ScreensSteven P Williams, Ultan McDermott
Molecular Oncology|June 25, 2014
Reading between the lines; understanding drug response in the post genomic eraConstantine C Alifrangis, Ultan McDermott
Methods in Enzymology|April 17, 2008
High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitorUltan McDermott, Sreenath V Sharma, Jeffrey Settleman
Clinical Colorectal Cancer|March 7, 2003
Predictive markers for colorectal cancer: current status and future prospectsDaniel B Longley, Ultan McDermott, Patrick G Johnston
Nature Cancer|February 5, 2022
Genomics-guided pre-clinical development of cancer therapiesHayley E Francies, Ultan McDermott, Mathew J Garnett
Pageof 12